• Explore /
  • Poster
  • / First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in patients (pts) with advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 Chinese subgroup analysis with 3-year follow-up.

First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in patients (pts) with advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 Chinese subgroup analysis with 3-year follow-up.

Abstract Poster

Authors

null

Lin Shen

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing, China;

Lin Shen , Yuxian Bai , Xiaoyan Lin , Wei Li , Jufeng Wang , Xiaochun Zhang , Hongming Pan , Chunmei Bai , Li Bai , Ying Cheng , Jingdong Zhang , Haijun Zhong , Yi Ba , Wenwei Hu , Rui-hua Xu , Weijian Guo , Shukui Qin , Rui Wang , Kendall Sullivan , Tianshu Liu

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers

Track

Esophageal and Gastric Cancer,Other GI Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT02872116

Citation

J Clin Oncol 41, 2023 (suppl 4; abstr 353)

DOI

10.1200/JCO.2023.41.4_suppl.353

Abstract #

353

Poster Bd #

E14

Abstract Disclosures

Similar Posters

First Author: Lin Shen

First Author: Kohei Shitara

First Author: Yelena Y. Janjigian

First Author: Ryan Sugarman